AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Vikas Ostwal

Vikas Ostwal

Tata Memorial Centre - Mumbai / India
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5715508
टाटा मेमोरियल सेंटर
person_outline Vikas Ostwal's MOST POPULAR ARTICLES
1-) Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Annals of Oncology 35 (5), 448-457, 2024
2-) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study The Lancet Gastroenterology & Hepatology 9 (8), 694-704, 2024
3-) Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo … The Lancet 405 (10474), 216-232, 2025
4-) Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open … The Lancet Gastroenterology & Hepatology 3 (12), 845-855, 2018
5-) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting ESMO open 9 (2), 102195, 2024